Compared to patients with a low CADILLAC risk score and a low C-reactive protein/albumin ratio (CAR), those with a high CADILLAC risk score and a high CAR had a significantly increased risk of 1-year major adverse cardiac events (adjusted HR 8.13).
Cohort (n=554)
No
Does combining the C-reactive protein/albumin ratio (CAR) with the CADILLAC risk score improve the prediction of 1-year MACE in patients with acute myocardial infarction undergoing primary PCI?
Combining the C-reactive protein/albumin ratio with the CADILLAC risk score significantly improves the prediction of 1-year major adverse cardiac events in patients with acute myocardial infarction undergoing primary PCI.
Hazard Ratio: 8.13 (95% CI 1.88–35.2)
p-value: p=0.005
Background: Acute myocardial infarction (AMI) remains a leading cause of morbidity and mortality, so accurate early risk stratification is essential for predicting adverse events. We investigated whether combining the Creactive protein/albumin ratio (CAR) with the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) risk score was associated with an increased risk of 1-year major adverse cardiac events (MACE), and assessed its efficacy in the risk stratification of patients with AMI undergoing primary percutaneous coronary intervention (PCI).
Oguri et al. (2026) conducted a cohort in Acute myocardial infarction (AMI) (n=554). High CADILLAC risk score and high C-reactive protein/albumin ratio (CAR) vs. Low CADILLAC risk score and low CAR was evaluated on 1-year major adverse cardiac events (MACE) (HR 8.13, 95% CI 1.88-35.2, p=0.005). Compared to patients with a low CADILLAC risk score and a low C-reactive protein/albumin ratio (CAR), those with a high CADILLAC risk score and a high CAR had a significantly increased risk of 1-year major adverse cardiac events (adjusted HR 8.13).